Solventum (SOLV) Competitors $66.83 +0.03 (+0.04%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SOLV vs. ZBH, SNN, PEN, GKOS, BLCO, INSP, PRCT, AXNX, NVCR, and NVSTShould you be buying Solventum stock or one of its competitors? The main competitors of Solventum include Zimmer Biomet (ZBH), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), PROCEPT BioRobotics (PRCT), Axonics (AXNX), NovoCure (NVCR), and Envista (NVST). These companies are all part of the "medical equipment" industry. Solventum vs. Zimmer Biomet Smith & Nephew Penumbra Glaukos Bausch + Lomb Inspire Medical Systems PROCEPT BioRobotics Axonics NovoCure Envista Zimmer Biomet (NYSE:ZBH) and Solventum (NYSE:SOLV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking. Do insiders & institutionals have more ownership in ZBH or SOLV? 88.9% of Zimmer Biomet shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ZBH or SOLV? Zimmer Biomet currently has a consensus price target of $123.33, suggesting a potential upside of 15.14%. Solventum has a consensus price target of $68.29, suggesting a potential upside of 2.18%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, research analysts clearly believe Zimmer Biomet is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 2 Sell rating(s) 11 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.25Solventum 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ZBH or SOLV more profitable? Zimmer Biomet has a net margin of 14.27% compared to Solventum's net margin of 0.00%. Zimmer Biomet's return on equity of 12.95% beat Solventum's return on equity.Company Net Margins Return on Equity Return on Assets Zimmer Biomet14.27% 12.95% 7.55% Solventum N/A N/A N/A Does the media refer more to ZBH or SOLV? In the previous week, Zimmer Biomet had 1 more articles in the media than Solventum. MarketBeat recorded 15 mentions for Zimmer Biomet and 14 mentions for Solventum. Solventum's average media sentiment score of 1.24 beat Zimmer Biomet's score of 0.77 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ZBH or SOLV? Zimmer Biomet received 899 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 67.16% of users gave Zimmer Biomet an outperform vote while only 5.56% of users gave Solventum an outperform vote. CompanyUnderperformOutperformZimmer BiometOutperform Votes90067.16% Underperform Votes44032.84% SolventumOutperform Votes15.56%Underperform Votes1794.44% Which has better valuation and earnings, ZBH or SOLV? Zimmer Biomet has higher earnings, but lower revenue than Solventum. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimmer Biomet$7.60B2.81$1.02B$5.2620.37Solventum$8.26B1.40N/AN/AN/A SummaryZimmer Biomet beats Solventum on 12 of the 14 factors compared between the two stocks. Ad ProsperityPubWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Solventum News Delivered to You Automatically Sign up to receive the latest news and ratings for SOLV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SOLV vs. The Competition Export to ExcelMetricSolventumSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$11.54B$4.34B$5.12B$19.18BDividend YieldN/A41.46%4.91%3.60%P/E RatioN/A25.3791.3441.28Price / Sales1.4045.961,117.7017.60Price / CashN/A43.4542.6421.28Price / BookN/A7.364.795.32Net IncomeN/A$13.64M$120.07M$989.88M7 Day Performance-3.92%-2.80%-1.90%-3.54%1 Month Performance-4.02%0.56%11.45%-3.68%1 Year PerformanceN/A41.87%30.63%12.14% Solventum Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SOLVSolventum1.3032 of 5 stars$66.83+0.0%$68.29+2.2%N/A$11.54B$8.26B0.0022,000Positive NewsZBHZimmer Biomet4.7353 of 5 stars$108.45+1.6%$122.83+13.3%-10.7%$21.59B$7.60B20.6818,000Dividend AnnouncementAnalyst UpgradeSNNSmith & Nephew3.7078 of 5 stars$25.50-0.1%N/A-7.3%$11.15B$5.55B13.0318,452News CoveragePENPenumbra4.2288 of 5 stars$248.69+1.3%$252.42+1.5%-1.8%$9.54B$1.16B285.524,200Analyst ForecastGKOSGlaukos4.115 of 5 stars$144.15+3.8%$143.17-0.7%+89.5%$7.95B$360.35M-46.00780Analyst ForecastShort Interest ↓BLCOBausch + Lomb2.9392 of 5 stars$18.61+0.1%$20.58+10.6%+16.9%$6.55B$4.68B-17.7113,300INSPInspire Medical Systems4.6549 of 5 stars$188.35+0.3%$233.58+24.0%+1.7%$5.64B$755.59M176.781,011Positive NewsPRCTPROCEPT BioRobotics2.7844 of 5 stars$89.54+0.3%$97.86+9.3%+102.9%$4.67B$136.19M0.00626Positive NewsAXNXAxonics1.4257 of 5 stars$70.98+0.8%$71.00+0.0%+20.9%$3.63B$366.38M-591.45610High Trading VolumeNVCRNovoCure2.7417 of 5 stars$32.91-1.5%$32.67-0.7%+138.4%$3.56B$577.74M-23.861,453NVSTEnvista3.9012 of 5 stars$19.55+0.4%$20.65+5.6%-21.1%$3.36B$2.50B-2.5112,800Positive News Related Companies and Tools Related Companies ZBH Alternatives SNN Alternatives PEN Alternatives GKOS Alternatives BLCO Alternatives INSP Alternatives PRCT Alternatives AXNX Alternatives NVCR Alternatives NVST Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:SOLV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solventum Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solventum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
